Informuta lands $1.3M NSF grant to bring antibiotic-resistance forecasting to hospitals
What's the deal? New Orleans startup InformutaDealroom has a profile for this one. Try Dealroom → has won a $1.25 million Small Business Innovation Research (SBIR) Phase II grant from the US National Science FoundationDealroom has a profile for this one. Try Dealroom →. The award funds its move from early validation to prospective clinical studies for a platform that forecasts antibiotic resistance before it emerges during treatment.
What's the endgame? Informuta is building what it calls a first-in-class capability: predicting how resistance is likely to evolve before it becomes clinically apparent. It combines whole-genome sequencing, proprietary genomic biomarkers, and artificial intelligence to quantify that future risk.
Why now? Standard antimicrobial susceptibility testing tells clinicians which antibiotics work at the moment a sample is tested. Those static snapshots miss whether resistance will emerge during treatment — a serious risk in high-acuity patients.
Where the money goes: The grant, which builds on an earlier NSF Phase I award, funds prospective validation with real clinical isolates, integration into hospital microbiology and antimicrobial stewardship workflows, and expansion of predictive models across priority pathogens. Informuta is running the work with University of Pittsburgh Medical CenterDealroom has a profile for this one. Try Dealroom →, its partner since Phase I, and University of California, IrvineDealroom has a profile for this one. Try Dealroom →.
New faces: Alongside the grant, Informuta expanded its leadership. Ryan Shields joined as chief medical officer, Ayesha Khan as vice president of clinical microbiology, and Barbara Zehentner as lab director — hires that strengthen the regulatory and quality infrastructure needed to move the technology into clinical use.
The competition: The grant is one of roughly 80 Phase II awards the National Science Foundation makes each year nationwide.
What could go wrong? Informuta still has to prove its predictions hold up inside real hospital workflows. "Phase II asks the harder and more important question: can we make that prediction reliably inside real hospital workflows and ultimately use it to help clinicians make better treatment decisions?" said co-founder and chief executive officer Kalen Hall.
The signal: Spun out of Tulane UniversityDealroom has a profile for this one. Try Dealroom → in 2023 and based at NOBICDealroom has a profile for this one. Try Dealroom →, Informuta reflects a wider push to make antimicrobial resistance predictable rather than reactive — turning promising lab science into deployable clinical infrastructure.
Read more: agilitypr.news
Image credit: Centers for Disease Control and Prevention
